Even though GM-CSF has a double-edged sword mechanism in cancer immunotherapy, our results show that the strategy of combining 9-ING-41 with HY-oAd-expressing GM-CSF does not negatively affect the eradication of bladder tumors. The gene discussed is CSF2; the disease is cancer.